What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Growth-hormone-releasing peptide-2 · Pralmorelin
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing GHRP-2 inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
GHRP-2 (also known as Pralmorelin) is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2; the D-2-naphthylalanine at position 2 is the defining residue of the molecule) and a GHSR (ghrelin / growth-hormone secretagogue receptor) agonist within the broader GHRP family. GHRP-2 produces robust GH release and was historically approved as a diagnostic agent for evaluating GH-secretory capacity, particularly in Japan where it has been used clinically as Pralmorelin. Compared with Ipamorelin (the GH-selective member of the family), GHRP-2 has somewhat broader receptor activity that also drives cortisol and prolactin release at higher doses, the trade-off being slightly larger GH-release magnitudes at the cost of less-clean receptor selectivity. PeptideXpo supplies GHRP-2 (Pralmorelin) as a lyophilized powder at ≥99.0% HPLC purity. The hexapeptide synthesis is straightforward, and the analytical packet covers peak-integration HPLC plus mass spec. Two standard fill sizes (5 mg and 10 mg) cover typical research workflows. For research workflows where clean GH-selectivity matters (avoiding cortisol-axis confounders), Ipamorelin is the more appropriate choice; GHRP-2 is preferred when maximum GH-release magnitude is the priority over receptor selectivity.
Who buys this, and why
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Frequently asked questions
Both peptides are GHSR (ghrelin receptor) agonists, but their selectivity profiles diverge meaningfully. Ipamorelin is highly selective for GHSR over the receptors that regulate cortisol, prolactin, and ACTH release, making it the cleanest GH-selective member of the GHRP family. GHRP-2 has broader activity, producing larger absolute GH-release magnitudes but with measurable secondary effects on cortisol and prolactin axes at higher doses. For research workflows where clean GH-selectivity matters (avoiding cortisol-axis confounders in cellular or in vivo readouts), Ipamorelin is the more appropriate choice; GHRP-2 is preferred when maximum GH-release amplitude is the primary endpoint. Both pair well with CJC-1295 in dual-pathway protocols, though the canonical commercial blend is built around Ipamorelin.
GHRP-2 was approved in Japan in 2006 under the generic name Pralmorelin (brand: GHRP Kaken) as a diagnostic agent for evaluating growth-hormone-secretory capacity in suspected adult GH deficiency. The approval was based on the molecule's reliable GH-release response in subjects with intact pituitary function and the absence of response in subjects with GH deficiency. The diagnostic-use indication remains the only approved indication for GHRP-2 in any major jurisdiction; the molecule is widely used as a research tool for GHSR pathway studies but lacks therapeutic-use approval. Buyers in Japan can reference the local clinical-use documentation; buyers elsewhere should treat GHRP-2 as a research-use compound.
